Nobel Prize Honors Optogenetics Pioneers

The 2026 Nobel Prize in Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for research that made it possible to control the activity of individual nerve cells using light. Their work underpins optogenetics, a technique now used in laboratories worldwide to investigate how the brain functions and how its activity relates to behaviour and disease. The research began with Hegemann’s study of how single-celled green algae move toward light. Hegemann and Nagel identified a protein that responds to blue light by opening a channel and producing an electrical impulse. Introducing the protein into other cells makes them sensitive to light. Deisseroth subsequently used the gene controlling the protein to develop a light-operated switch for nerve cells in the brains of living mice. The Nobel Assembly said optogenetics had opened a new era in neuroscience by helping researchers trace pathways connected to behaviour and disease. Deisseroth is based at Stanford University in California; Hegemann works at Humboldt University in Berlin, and Nagel at the University of Würzburg in Germany. The prize was announced at Stockholm’s Karolinska Institute, opening Nobel week. The award is worth 12 million Swedish kronor, approximately $1.718 million. The announcements for physics, chemistry, literature and peace follow during the week, with the economics prize scheduled for October 12. Last year’s medicine prize recognized research into the immune system.

The Nobel Prize in medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for research explaining how individual nerve cells can be switched on and off. Their work centers on light-gated ion channels and optogenetics, methods that use light to control and study nerve cells. The Nobel committee said the approach is now used in laboratories around the world to investigate the brain. Deisseroth is based at Stanford University in California. Hegemann works at Humboldt University in Berlin, and Nagel is at the University of Würzburg. Thomas Perlmann, secretary of the medicine committee, said he had reached all three winners by telephone on Monday. The award was announced at Stockholm’s Karolinska Institute, opening Nobel week. The three recipients will divide a prize of 12 million Swedish kronor, equivalent to approximately 1.2 million US dollars. The article notes that the previous year’s medicine prize recognized three scientists for research on the immune system. It also sets out the schedule for the remaining awards: physics on Tuesday, chemistry on Wednesday, literature on Thursday, and the peace prize on Friday. The Nobel Memorial Prize in Economic Sciences is scheduled to be announced on October 12. Overall, the article reports the laureates, the scientific significance and institutional use of their research, and the timing and context of the award within the annual Nobel announcements.

Karl Deisseroth, Peter Hegemann and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine for their contributions to optogenetics, a technique that lets researchers control nerve-cell activity using light. The Nobel Committee said their work established the foundation for a new era in neuroscience by enabling scientists to switch particular neural circuits on or off, helping them investigate the brain processes involved in memories, feelings and behaviours, including those relevant to psychiatric and neurological disorders. Hegemann and Nagel discovered channelrhodopsin, a light-sensitive protein originating in algae, in the early 2000s. Deisseroth developed a way to use the protein to activate nerve cells in mice. Researchers have since used optogenetics to study cells and pathways in animals, gaining insight into the nervous system and its interactions with other parts of the body, including the heart and gut. The Nobel Assembly described the technique as having fundamentally changed scientists’ understanding of the brain and said it was helping address the question of how the brain works. The article also describes potential clinical applications. Researchers are testing optogenetics as a treatment for vision loss caused by retinitis pigmentosa, which damages the eye’s rods and cones. In clinical trials, a light-sensitive protein has been introduced into damaged areas of the eye. One patient regained some vision while wearing special glasses that emit light to activate the protein. The three laureates will share the prize of 12 million Swedish kronor, reported as approximately £900,000. They described receiving the award as “absolutely wonderful” and an honour to share with friends.

Karl Deisseroth, Peter Hegemann and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine for discoveries involving light-gated ion channels and optogenetics. The technique allows researchers to use light to switch individual nerve cells on or off in a living brain, helping scientists investigate how brain cells communicate and process information. The three scientists will share the prize of 12 million Swedish crowns, equivalent to about $1.7 million Canadian. Deisseroth works at Stanford University, while Hegemann and Nagel are based at Humboldt University in Berlin and the University of Würzburg, respectively. The article traces the work back to Hegemann’s early-1990s research into how the alga Chlamydomonas responds to light. Nagel’s experiments identified channelrhodopsin-2, a light-sensitive ion channel. In 2003, the researchers showed that the protein could be introduced into human and hamster cells to generate electrical impulses using light. Deisseroth demonstrated the technique in rat nerve cells in 2005; it became known as optogenetics the following year. Researchers now use the method in laboratories worldwide, and it may have potential clinical applications. Clinical trials are investigating whether light-sensitive proteins can help restore vision in people with retinitis pigmentosa by activating healthy retinal cells that remain after photoreceptors are lost. Researchers also hope the approach could enable more precise stimulation of the auditory nerve in cochlear implants. Nobel committee members described the work as opening a new era in neuroscience, while emphasizing that the field is still developing. The article also notes that the Nobel Prizes were established under Alfred Nobel’s will and are presented on December 10, the anniversary of his death.

The 2026 Nobel Prize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for discoveries involving light-gated ion channels and optogenetics. Optogenetics combines optics and genetics to let researchers use light to stimulate neurons. The Nobel Assembly says the technique has transformed understanding of the brain by enabling researchers to investigate neural circuits associated with memories, feelings and behaviors, including those relevant to neurological and psychiatric disorders. The article describes potential applications beyond basic research. Optogenetics has helped researchers study how brain circuits are disrupted in conditions such as blindness, depression, addiction and dementia. Scientists are also investigating its use to restore sight in people with visual impairment, and hope it may contribute to treatments for disorders including Parkinson’s disease and epilepsy. Hegemann, a photobiology expert and professor of neuroscience at Humboldt University of Berlin, and Nagel, a biophysicist and professor of neurophysiology at the University of Würzburg, studied a protein found in green algae. They found that blue light causes the protein to open a channel, producing an electrical impulse; putting the protein into other cells makes those cells sensitive to light. Deisseroth, a Stanford University professor of bioengineering and psychiatry and behavioral sciences, subsequently worked with the gene controlling the protein to develop a light-controlled switch for nerve cells in living mice. The medicine award is the first Nobel Prize announced that week. Awards in physics, chemistry, literature and peace were scheduled to follow. The article also notes that the previous year’s medicine prize went to Mary Brunkow, Fred Ramsdell and Shimon Sakaguchi for discoveries concerning peripheral immune tolerance. The prizes are to be presented in Stockholm on December 10, with each carrying 12 million Swedish kronor.

The 2026 Nobel Prize in Physiology or Medicine was jointly awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for research on light-gated ion channels and optogenetics. Their work concerns ways to use light to switch the activity of individual nerve cells on or off, helping researchers investigate how the brain functions. The Nobel committee praised the method, saying it is now used in laboratories around the world to explore the brain’s mysteries. The laureates are based at universities in the United States and Germany. Deisseroth is at Stanford University in California; Hegemann is at Humboldt University in Berlin; and Nagel is at the University of Wurzburg in Germany. They are 54, 71 and 73, respectively, according to the article. The award was announced at the Karolinska Institute in Stockholm, opening Nobel week. The article notes that the previous year’s medicine prize went to three scientists whose research concerned the immune system. The week’s remaining announcements include physics on Tuesday, chemistry on Wednesday and literature on Thursday. The Peace Prize is scheduled for Friday, followed by the Nobel Memorial Prize in Economic Sciences on October 12. The prize amount this year is 12 million Swedish kronor, approximately $1.2 million. The article says this amount applies whether the award goes to an individual, a small group of laureates or an organisation. The report was published by France 24 with material from the Associated Press.

France 24 reports that the Nobel Prize in Medicine was awarded to US psychiatrist and neurologist Karl Deisseroth and German scientists Peter Hegemann and Georg Nagel for pioneering work in optogenetics. The article describes optogenetics as a neuroscience technique that uses light to control neurons. It notes that the research could potentially contribute to breakthroughs for conditions including dementia, depression and blindness. The report is presented by France 24’s Monte Francis. The supplied article text contains only a brief description and does not provide further details about the scientists’ discoveries, the prize citation, or how the technique might be applied to those conditions.

American neuroscientist Karl Deisseroth and German scientists Peter Hegemann and Georg Nagel won the 2026 Nobel Prize in Physiology or Medicine for their work developing optogenetics. The technique uses light-sensitive proteins to control the activity of individual nerve cells in a living brain, allowing researchers to switch targeted neurons on or off and study how brain circuits function. The Nobel Assembly at Sweden’s Karolinska Institute recognized the trio for discoveries concerning light-gated ion channels and optogenetics. The laureates will share a prize of 12 million Swedish crowns, or about US$1.2 million. The work began with research into how the alga Chlamydomonas responds to light. In the early 1990s, Hegemann investigated the alga’s rapid response and proposed that one protein might both capture light and function as an ion channel. Nagel tested the idea by introducing algal genes into frog eggs, identifying channelrhodopsin-2, a light-sensitive ion channel. In 2003, Hegemann and Nagel reported that the protein could be introduced into human cells to trigger electrical impulses with light. Deisseroth demonstrated the approach in rat nerve cells in 2005, and the technique was named optogenetics in 2006. Deisseroth’s interest in understanding the brain was shaped in part by encountering psychiatric patients he could not help as a trainee neurosurgeon. Researchers have since used optogenetics to investigate brain activity and behavior in animals, including controlling mouse whisker movements and waking sleeping mice. The work is providing insights into disorders such as schizophrenia, Alzheimer’s disease, Parkinson’s disease, epilepsy and addiction, though these investigations use animal models and are intended to help identify avenues for human research. Potential applications under development include restoring some vision in people with retinitis pigmentosa by inserting a light-sensitive protein into the retina, and improving cochlear implants through more precise stimulation of the auditory nerve. The article presents optogenetics as a major research advance while emphasizing that its clinical possibilities are still being explored.

The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for research into light-gated ion channels and optogenetics. Their work concerns mechanisms that allow the brain to switch the activity of individual nerve cells on or off. The Nobel committee said the method is now used in laboratories around the world to investigate the brain. Deisseroth is based at Stanford University in California; Hegemann works at Humboldt University in Berlin, and Nagel at the University of Würzburg in Germany. The award was announced Monday at the Karolinska Institute in Stockholm, beginning the annual week of Nobel Prize announcements. Medicine committee secretary Thomas Perlmann said he reached all three recipients by phone. The prize is worth 12 million Swedish kronor, approximately $1.2 million, whether awarded to one recipient, a small group or an organization. The article notes that last year’s medicine prize went to three researchers studying the immune system. The week’s other announcements include physics on Tuesday, chemistry on Wednesday, literature on Thursday, the peace prize on Friday, and the economics prize on October 12. The report is attributed to The Associated Press and includes a photograph caption identifying the laureates as they appeared during the announcement at the Nobel Forum at Karolinska Institutet.

The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for research that enabled optogenetics, a technique for controlling and studying nerve-cell activity with light. Their work centers on light-gated ion channels, proteins that can trigger electrical impulses when exposed to light. The Nobel Assembly said optogenetics is now used in laboratories around the world to investigate the brain. The research began with Hegemann’s investigation of how single-celled green algae swim toward light. Hegemann and Nagel identified a protein that opens a channel and produces an electrical impulse when illuminated with blue light. By introducing the protein into other cells, researchers can make those cells responsive to light. Deisseroth used the gene controlling the protein to develop a light-controlled switch for nerve cells in the brains of living mice. This approach lets scientists turn nerve cells and circuits on or off, helping them study how brain pathways relate to behavior and disease. The three laureates are affiliated with Stanford University in California, Humboldt University in Berlin and the University of Würzburg in Germany. Medicine committee secretary Thomas Perlmann said he reached all three by phone after the announcement; the Associated Press had not immediately reached them. The award was announced at Stockholm’s Karolinska Institute, beginning the week of Nobel announcements. The prize is worth 12 million Swedish kronor, approximately $1.2 million. The medicine award was followed by prizes in physics, chemistry, literature and peace, with the economics prize scheduled for October 12. The previous year’s medicine prize had gone to three researchers for work on the immune system.

American neuroscientist Karl Deisseroth and German scientists Peter Hegemann and Georg Nagel have won the 2026 Nobel Prize in Physiology or Medicine for research that led to optogenetics. The Nobel Assembly at Sweden’s Karolinska Institute recognized their discoveries concerning light-gated ion channels and the development of the technique. Optogenetics uses light to control the activity of individual nerve cells in the brain, allowing researchers to switch cells on or off in a living brain. The three laureates will share a prize of 12 million Swedish crowns, reported as approximately US$1.2 million. Thomas Perlmann, secretary general of the Nobel Assembly, said laboratories around the world now use the method to investigate the brain. The article presents the award and the technique’s scientific significance, with no further details about the researchers’ individual contributions or the history of their work.

Karl Deisseroth, Peter Hegemann and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine for discoveries concerning light-gated ion channels and optogenetics. The three scientists will share the prize of 12 million Swedish kronor. Optogenetics uses light-sensitive proteins to control the activity of individual nerve cells in a living brain, enabling researchers to investigate brain function. The method is now used in laboratories worldwide. The article traces the work leading to the technique. In the early 1990s, Hegemann studied how the alga Chlamydomonas responds to light and proposed that a protein could both capture light and function as an ion channel. Nagel tested the idea by introducing algal genes into frog eggs, identifying channelrhodopsin-2, which opens in response to light. In 2003, the researchers reported that the protein could produce electrical impulses when introduced into human and hamster cells. Deisseroth demonstrated the technique in rat nerve cells in 2005; the method became known as optogenetics the following year. The award announcement highlighted possible medical applications. Clinical trials are investigating whether light-sensitive proteins inserted into the retina can restore sight to people with retinitis pigmentosa. Researchers also hope the technique could make cochlear implants more precise by stimulating the auditory nerve with greater accuracy than current electrical devices. Nobel Assembly secretary-general Thomas Perlmann said the laureates were surprised and delighted to receive the award together, and described them as friends. The article also outlines the history and traditions of the Nobel Prizes. The five original prizes, established under Alfred Nobel’s will, have been awarded since 1901, while the economics prize was created in 1968. Medicine laureates have included Alexander Fleming for penicillin and Karl Landsteiner for the discovery of human blood groups. The annual award announcements begin with medicine, and the ceremonies culminate on Dec 10 in Stockholm, except for the Peace Prize ceremony, which takes place in Oslo.

The article reports that the Nobel Prize in Physiology or Medicine has been awarded to three scientists for work on optogenetics: American neuroscientist Karl Deisseroth and German scientists Peter Hegemann and Georg Nagel. The article identifies Deisseroth as a professor at Stanford University, Hegemann as being from Humboldt University, and Nagel as working at the University of Würzburg. It says their discoveries have revealed more about how the brain functions, but the supplied article text does not explain the discoveries, describe optogenetics in detail, or provide further comments from the laureates or the Nobel committee. The material provided is a brief opening rather than a full account of the prize announcement. It contains no detail about the scientists’ individual contributions, the research history, possible applications, or the selection process. Related-story links and a sign-up prompt appear after the opening, but they are website recommendations and promotional material rather than part of the article’s reporting. Accordingly, the central takeaway is limited but clear: the Nobel recognition honors three researchers whose optogenetics work has advanced understanding of brain function. The award is presented as a major scientific achievement, while the excerpt itself offers little context beyond the laureates’ names, affiliations, and the broad significance of their discoveries.